Cartesian Therapeutics, Inc. (RNAC)
10.17
+0.13
(+1.29%)
USD |
NASDAQ |
Aug 24, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -688.5% |
| December 31, 2025 | 35.80% |
| September 30, 2025 | -34.07% |
| June 30, 2025 | -97.65% |
| March 31, 2025 | -5.09% |
| September 30, 2024 | 26.10% |
| June 30, 2024 | 99.41% |
| March 31, 2024 | 96.87% |
| December 31, 2023 | 96.71% |
| September 30, 2023 | 97.11% |
| June 30, 2023 | 88.07% |
| March 31, 2023 | 89.63% |
| December 31, 2022 | 96.39% |
| September 30, 2022 | 97.40% |
| June 30, 2022 | 98.73% |
| March 31, 2022 | 98.11% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| Date | Value |
|---|---|
| September 30, 2020 | 0.00% |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.00% |
| September 30, 2019 | |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| March 31, 2015 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Allogene Therapeutics, Inc. | 43.00% |
| Beam Therapeutics, Inc. | -1.00K% |
| C4 Therapeutics, Inc. | 73.05% |
| Kyverna Therapeutics, Inc. | -- |
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -46.23% |
| Return on Net Operating Assets | -84.36% |